ABCG2 and cancer: In summary, we revealed that the second-generation PIM kinase inhibitor TP-3654 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs by attenuating the drug efflux function of ABCG2 (Figure 6).